Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Therakos, a Johnson & Johnson company, has received the FDA approval for its Therakos Cellex photopheresis system for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma that are unresponsive to other forms of treatment.
Subscribe to our email newsletter
According to the company, the Therakos Cellex photopheresis system is an easy-to-use, integrated system that uses extracorporeal photopheresis, a cellular therapy, to relieve the symptoms of cutaneous T-cell lymphoma (CTCL). The system also has been cleared recently in Canada and Europe.
Michael Yang, general manager of Therakos, said: “The new features of the Therakos Cellex photopheresis system were designed specifically to create a better treatment experience for both patients and the health care professionals administering the therapy. This new system is an example of a medical device and a drug therapy combining in a unique and innovative way to deliver favorable outcomes for patients.”